Skip to content
DataLookout
Menu

No-PAINNCT05842044

NSAID Use After Robotic Partial Nephrectomy

StatusActive, Not Recruiting
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 9 versions: 8 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Enrollment closed, study ongoing
    • Final enrollment: 137 participants (planned 110)
    • Primary completion date changed from estimate of Sep 30, 2026 to Oct 9, 2026
    • Site details revised
  2. Notable Eligibility criteria expanded, about 12 words
    • Study completion pushed from Sep 30, 2026 to Dec 31, 2026
    • Secondary endpoints: details revised at 2 of 5 entries
  3. Notable Primary and study completion dates: Sep 30, 2025 to Sep 30, 2026v7
  4. Minor Primary and study completion dates: Sep 5, 2025 to Sep 30, 2025
    • Start date: Sep 5, 2023 to Sep 15, 2023
    • Secondary endpoints: details revised at 4 of 5 entries
    v5
  5. Notable Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v4
Show 2 earlier versionsHide 2 earlier versions
  1. Minor Primary and study completion dates: Aug 31, 2025 to Sep 5, 2025
    • Start date: Aug 31, 2023 to Sep 5, 2023
    v3
  2. Notable Start date: Jul 31, 2023 to Aug 31, 2023
    • Primary and study completion dates: Jul 31, 2025 to Aug 31, 2025
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Rate of Opioid Use in Postoperative Period
Timeframe: Up to 20 days

Secondary (5)

Rate of Opioid Medication Use during Hospitalization
Pain Score Assessed by Standardized Script
Pain Score Assessed by International Pain Outcome Questionnaire
Number of Treatment-Related Adverse Events
Change in Rate of Acute Kidney Injury

Arms and interventions

Group 1: NSAIDExperimental

Participants in this group will be prescribed NSAIDs instead of the standard of care treatment. Participants will be in this group for approximately 21 days.

Group 2: No-NSAIDActive comparator

Participants in this group will follow standard of care treatment. Participants will be in this group for approximately 21 days.

Drugs: Ketorolac, Acetaminophen, Oxycodone, Hydromorphone, Ibuprofen

Sites

1 site in 1 country

  • University of MiamiMiami, Florida, United States